Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non–Small-Cell Lung Cancer

Abstract

Purpose Treatment guidelines for advanced non–small-cell lung cancer (aNSCLC) recommend broad molecular profiling for targeted therapy selection. This study prospectively assessed comprehensive next-generation sequencing (NGS) of cell-free circulating tumor DNA (cfDNA) compared with standard-of-care (SOC) tissue-based testing to identify guideline-recommended alterations in aNSCLC. PATIENTS AND METHODS Patients with treatment-naïve aNSCLC were tested using a well-validated NGS cfDNA panel, and results were compared with SOC tissue testing. The primary objective was noninferiority of cfDNA vs. tissue analysis for the detection of two guideline-recommended biomarkers ( EGFR and ALK) and an additional six actionable biomarkers. Secondary analyses included tissue versus cfDNA biomarker discovery, overall response rate (ORR), progression-free survival (PFS) to targeted therapy, and positive predictive value (PPV) of cfDNA. RESULTS The primary objective was met with cfDNA identifying actionable mutations in 46 patients versus 48 by tissue ( P < .05). In total, 0/186 patients were genotyped for all eight biomarkers with tissue, compared with 90.8% using cfDNA. Targetable alterations or KRAS were identified in 80.7% when cfDNA was used first versus 57.1% when tissue was used first. PPV for cfDNA-detected EGFR was 100.0% (25/25). ORR and PFS in patients receiving targeted therapy based on tissue or cfDNA were similar to those previously reported. Conclusion This prospective study confirms a previous report that comprehensive cfDNA testing is noninferior to SOC tissue testing in detecting aNSCLC-recommended biomarkers. Furthermore, cfDNA-based first-line therapy produced outcomes similar to tissue-based testing, demonstrating the clinical utility of comprehensive cfDNA genotyping as the initial genotyping modality in patients with treatment-naïve aNSCLC when tissue is insufficient or when all actionable biomarkers cannot be rapidly assessed.

A clinician’s handbook for using ctDNA throughout the patient journey

“…ORR and PFS in patients receiving targeted therapy based on tissue or cfDNA were similar to those previously reported. Confirms that cfDNA-based first-line therapy produced outcomes similar to tissue-based testing [ 98 ]. TARGET Feasibility and screening trial Solid tumors 100 641 cancer-associated-gene panel in a single ctDNA assay Two-part study divided into Part A, feasibility of the workflow, ctDNA and tumor sequencing validation, formal reporting and setting up the MTB; and Part B, expansion to match patients to clinical trials and therapies in real time Four patients experienced an objective response, which represents 36% of the treated patients and 4% of the whole included cohort.…”

Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations

“…With the complexity of possible molecular resistance mechanisms across different oncogenic driver alterations and different TKIs, which in general include on target secondary mutations and off target pathway activations, cfDNA testing methodologies have moved from single gene assays to highly sensitive NGS panels [40]. Also for patients, who have inadequate tissue DNA available for initial molecular testing, liquid biopsy offers a non-invasive approach for molecular profiling [13,41,42]. Importantly, the detection of a targetable mutation in ctDNA is sufficient to initiate targeted treatment [43].…”

Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment

“…Importantly, the ctDNA median turnaround time was faster than tissue (9 vs 15 days; P < 0.0001) [83]. We conducted a similar prospective study in Spain [84] in 186 NSCLC patients, confirming that the Guardant360 NGS ctDNA assay was not inferior to standard-ofcare tissue testing in detecting recommended biomarkers, further confirming that ctDNA-based first-line therapy produces outcomes similar to tissue-based testing [84].…”